• Uremic Metabolite Adsorption on Hydroxy-PEO Films

  2026-08-13

  The 2025 study shows that hydroxy-terminated polyethylene oxide films do not interact uniformly with uremic metabolites: adsorption depends on chain density, exposure time, and metabolite structure. Its multi-component design moves low-fouling biomaterial research closer to the chemical complexity of kidney failure blood and provides a framework for testing metabolite-specific surface interactions.

• Ibrexafungerp (MK 3118): Mechanism and Evidence

  2026-08-12

  Ibrexafungerp, also called MK 3118, is an oral triterpenoid antifungal that inhibits fungal 1,3-β-D-glucan synthase. Evidence supports activity against resistant Candida, including Candida auris, while clinical approval currently centers on vulvovaginal candidiasis and recurrent VVC prevention.

• Diuron-Induced Acute Renal Injury: JAK2/STAT1

  2026-08-12

  The reference study integrates network toxicology, transcriptomic validation, molecular docking, and HK-2 cell experiments to investigate how Diuron may cause acute kidney injury. Its central finding is that JAK2/STAT1 signaling is associated with Diuron-induced renal toxicity, providing a mechanistic framework for environmental exposure assessment while highlighting the need for further validation in physiologically relevant models.

• MEK/ERK Control of TERT in Human Stem Cells

  2026-08-11

  This preprint identifies a signaling–epigenetic mechanism that sustains TERT transcription in human pluripotent stem cells: MEK1/2–ERK1/2 activity and c-Myc:MAX cooperate to oppose PRC2-associated repression at the TERT promoter. The findings connect MAPK signaling to telomere maintenance and provide a framework for interpreting ERK-pathway perturbation in stem-cell and cancer research.

• AmpC/AmpD Resistance to Ceftolozane-Tazobactam

  2026-08-10

  Deroche and colleagues combined allelic reconstruction, sequential time-kill experiments, and semi-mechanistic PK/PD modeling to separate the immediate and adaptive effects of AmpC and AmpD mutations on ceftolozane-tazobactam activity. The work shows why endpoint susceptibility alone may underestimate resistance dynamics and provides a framework for interpreting treatment-emergent resistance in clinical Pseudomonas aeruginosa isolates.

• Prednisolone: A Rigorous Assay Design Guide

  2026-08-09

  Prednisolone is a synthetic glucocorticoid for dissecting receptor-driven inflammation and immune signaling. This guide distinguishes steroid pharmacology from ERAD-based protein degradation and translates that distinction into more reliable assay design.

• S1P/S1PR3 Signaling in Neuronal Apoptosis After ICH

  2026-08-08

  The reference study identifies S1PR3 as a receptor-level driver of neuronal apoptosis after acute intracerebral hemorrhage and connects it to TNF-α, PI3K/AKT, and cleaved caspase-3 signaling. By combining a mouse ICH model with S1P-stimulated HT22 cells and pharmacological S1PR3 inhibition, the work provides a mechanistic framework for evaluating S1PR3 as a neuroprotection target.

• CX-4945: Practical CK2 Inhibition Workflows

  2026-08-07

  CX-4945 (Silmitasertib) provides a practical chemical tool for connecting CK2 activity with signaling, apoptosis, cell-cycle behavior, and aggressive lung-cancer phenotypes. This guide translates the ECE-1c study into reproducible treatment, stability, chemoresistance, and invasion workflows, with troubleshooting for common assay failures.

• SCUBE3 Antibody Targeting Inhibits Cancer Growth and Immune

  2026-08-07

  This study identifies SCUBE3 as a critical driver of tumor progression, therapy resistance, and immunosuppression in diverse cancers. By developing a first-in-class neutralizing antibody targeting SCUBE3, researchers demonstrate potent suppression of oncogenic signaling and restoration of antitumor immunity, offering a promising new strategy for pan-cancer therapy.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-08-06

  Schwartz's dissertation presents a rigorous analysis of in vitro assessment methods for anti-cancer drug responses, distinguishing between proliferative arrest and cell death. Her work highlights the importance of precise viability metrics and offers methodological improvements for interpreting complex cancer drug effects.

• Cdk5 Downregulation Mitigates Hippocampal Neuron Ferroptosis

  2026-08-06

  This study demonstrates that inhibiting Cdk5 alleviates ferroptosis in hippocampal neurons after ischemic stroke by modulating the AMPK pathway and microglial polarization. The findings highlight a mechanistic link between Cdk5, neuroinflammation, and iron-dependent neuronal death, informing strategies for targeted neuroprotection.

• Entecavir (BMS200475): Optimizing HBV Replication Inhibition

  2026-08-05

  Entecavir (BMS200475) stands out as a selective and potent tool for chronic hepatitis B virus replication inhibition, offering robust performance even against lamivudine-resistant strains. This article dissects applied workflows, troubleshooting strategies, and novel insights from recent meta-analytic research, equipping laboratories with practical guidance for maximizing assay success and translational impact.

• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe Gui

  2026-08-05

  DiI (DiIC18(3)) is a lipophilic orange fluorescent dye optimized for selective plasma membrane labeling in live and fixed cells. It is not suitable for aqueous-only protocols or intracellular organelle labeling, and requires strict adherence to solvent compatibility and membrane integrity protocols for reliable results.

• Paclitaxel (Taxol): Strategic Insights for Translational Onc

  2026-08-04

  This article delivers advanced, evidence-based guidance on leveraging Paclitaxel (Taxol) for translational cancer research, integrating mechanistic depth, protocol optimization, and clinical relevance. By bridging recent literature—including BH3 mimetic strategies and FOXM1-mediated resistance—this piece offers actionable insight beyond standard product pages, equipping researchers to design more predictive models and accelerate therapeutic innovation.

• YM 58483 (BTP2): Advanced SOCE Blockade for Immune and Fibro

  2026-08-04

  Explore the advanced scientific applications of YM 58483 (BTP2), a potent SOCE blocker, in immune modulation and fibrosis models. Discover how its unique selectivity and mechanistic insights from recent literature can inform experimental design and translational research.

449 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page